Clinical hematology international最新文献_第2页

Allogeneic and other innovative chimeric antigen receptor platforms. 异体和其他创新型嵌合抗原受体平台。

Clinical hematology international Pub Date : 2024-09-27 eCollection Date: 2024-01-01 DOI: 10.46989/001c.121404

Andrew P Jallouk, Salyka Sengsayadeth, Bipin N Savani, Bhagirathbhai Dholaria, Olalekan Oluwole

引用次数: 0

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. 意义未定的单克隆丙种球蛋白病和烟雾型多发性骨髓瘤患者的心理影响。

Clinical hematology international Pub Date : 2024-09-24 eCollection Date: 2024-01-01 DOI: 10.46989/001c.123608

Tanvi H Patel, Ramya Bachu, Trilok Shrivastava, Jawad Alrawabdeh, Marah Alzubi, Jael Hastings, Harold Dean, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Guido Tricot, Fenghuang Zhan, John D Shaughnessy, Frits van Rhee, Samer Al Hadidi

引用次数: 0

The acceptability of using wearable electronic devices to monitor physical activity of patients with Multiple Myeloma undergoing treatment: a systematic review. 使用可穿戴电子设备监测接受治疗的多发性骨髓瘤患者体力活动的可接受性：系统性综述。

Clinical hematology international Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.46989/001c.121406

Tommy Brown, Ann Muls, Charlotte Pawlyn, Kevin Boyd, Susanne Cruickshank

{"title":"The acceptability of using wearable electronic devices to monitor physical activity of patients with Multiple Myeloma undergoing treatment: a systematic review.","authors":"Tommy Brown, Ann Muls, Charlotte Pawlyn, Kevin Boyd, Susanne Cruickshank","doi":"10.46989/001c.121406","DOIUrl":"https://doi.org/10.46989/001c.121406","url":null,"abstract":"Introduction: Multiple myeloma (MM) is diagnosed in 6,000 people in the UK yearly. A performance status measure, based on the patients' reported level of physical activity, is used to assess patients' fitness for treatment. This systematic review aims to explore the current evidence for the acceptability of using wearable devices in patients treated for MM to measure physical activity directly.Methods: Three databases were searched (MEDLINE, EMBASE and CINAHL) up until 7th September 2023. Prospective studies using wearable devices to monitor physical activity in patients on treatment for MM were included. Bias across the studies was assessed using the CASP tool.Results: Nine studies, with 220 patients on treatment for MM, were included. Only two studies had a low risk of bias. Different wearable device brands were used for varying lengths of time and were worn on either the wrist, upper arm, or chest. Adherence, reported in seven studies, ranged from 50% to 90%. Six studies reported an adherence greater than 75%. Although physical activity was also measured in a heterogenous manner, most studies reported reduced physical activity during treatment, associated with a higher symptom burden.Conclusion: Monitoring patients receiving treatment for MM with a wearable device appears acceptable as an objective measure to evaluate physical activity. Due to the heterogeneity of the methods used, the generalisability of the results is limited. Future studies should explore the data collected prospectively and their ability to predict relevant clinical outcomes.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SARS-CoV2 is not just infection but a culprit of donor graft failure post-allogeneic stem cell transplant. SARS-CoV2 不仅是感染，也是异体干细胞移植后供体移植物失败的罪魁祸首。

Clinical hematology international Pub Date : 2024-07-26 eCollection Date: 2024-01-01 DOI: 10.46989/001c.121430

Yoojin Park, Silvia Park, Wichai Chinratanalab, Bipin Savani, Adetola Kassim, Jonathan J Douds, Salyka Sengsayadeth, Tae Kon Kim

引用次数: 0

The doctor, the patient, and the computer. 医生、病人和电脑。

Clinical hematology international Pub Date : 2024-07-23 eCollection Date: 2024-01-01 DOI: 10.46989/001c.121434

Finn Bo Petersen, Mohamad Mohty, Didier Blaise

引用次数: 0

The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge. EMMY 纵向队列研究：随着更多治疗方案的出现，用真实世界的数据描述多发性骨髓瘤的管理和疗效。

Clinical hematology international Pub Date : 2024-07-23 eCollection Date: 2024-01-01 DOI: 10.46989/001c.121371

Olivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, Margaret Macro, Laurent Frenzel, Aurore Perrot, Philippe Moreau, Bruno Royer, Denis Caillot, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Pierre Feugier, Sophie Rigaudeau, Jean Fontan, Cécile Sonntag, Laure Vincent, Thomas Chalopin, Herve Avet Loiseau, Zakaria Maarouf, Louni Chanaz, Nathalie Texier, Cyrille Hulin

{"title":"The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.","authors":"Olivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, Margaret Macro, Laurent Frenzel, Aurore Perrot, Philippe Moreau, Bruno Royer, Denis Caillot, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Pierre Feugier, Sophie Rigaudeau, Jean Fontan, Cécile Sonntag, Laure Vincent, Thomas Chalopin, Herve Avet Loiseau, Zakaria Maarouf, Louni Chanaz, Nathalie Texier, Cyrille Hulin","doi":"10.46989/001c.121371","DOIUrl":"https://doi.org/10.46989/001c.121371","url":null,"abstract":"The therapeutic management of patients with multiple myeloma (MM) is complex. Despite substantial advances, MM remains incurable, and management involves cycles of treatment response, disease relapse, and further therapy. Currently, evidence to support the therapeutic decision is limited. Thus, the EMMY longitudinal, real-world study was designed to annually assess therapeutic management of MM in France to provide evidence to support physicians. During an annual prespecified 3-month recruitment period, eligible patients will be identified from their medical records. Adults aged ≥18 years diagnosed with symptomatic MM and requiring systemic treatment will be eligible. The primary objective, the evolution of MM therapeutic management, will be described, as well as the impact on the following outcomes: time-to-next treatment (TTNT), progression-free survival (PFS), and overall survival (OS). The study plans to recruit 5000 patients over 6 years: 700 to 900 patients annually. EMMY is a unique opportunity to collect real-world data to describe the evolving MM therapeutic landscape and record outcomes in France. These data will provide annual snapshots of various aspects of MM management. This knowledge will provide physicians with real-life, evidence-based data for therapeutic decision-making and ultimately improve treatment for MM patients.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standing on the Shoulders of the Giants: Dr. Kanti R Rai. 站在巨人的肩膀上康提-拉伊博士

Clinical hematology international Pub Date : 2024-07-22 eCollection Date: 2024-01-01 DOI: 10.46989/001c.121408

Mohamad Mohty, Kanti Rai

引用次数: 0

Scientific writing: how to get published. 科学写作：如何发表文章。

Clinical hematology international Pub Date : 2024-07-12 eCollection Date: 2024-01-01 DOI: 10.46989/001c.120878

Junia Melo, Mohamad Mohty

引用次数: 0

Total body irradiation-based conditioning versus chemotherapy before allogeneic stem cell transplantation for adults with acute lymphoblastic leukemia. 成人急性淋巴细胞白血病患者异基因干细胞移植前全身照射调理与化疗的比较。

Clinical hematology international Pub Date : 2024-07-12 eCollection Date: 2024-01-01 DOI: 10.46989/001c.120991

Nour Ben Abdeljelil, Rihab Ouerghi, Insaf Ben Yaiche, Sabrine Mekni, Lamia Torjemane, Dorra Belloumi, Rimel Kanoun, Ines Turki, Chiraz Nasr-Ammar, Saloua Ladeb, Tarek Ben Othman

引用次数: 0

Single-cell genomics-based immune and disease monitoring in blood malignancies. 基于单细胞基因组学的血液恶性肿瘤免疫和疾病监测。

Clinical hematology international Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI: 10.46989/001c.117961

Anja C Rathgeber, Leif S Ludwig, Livius Penter

{"title":"Single-cell genomics-based immune and disease monitoring in blood malignancies.","authors":"Anja C Rathgeber, Leif S Ludwig, Livius Penter","doi":"10.46989/001c.117961","DOIUrl":"10.46989/001c.117961","url":null,"abstract":"Achieving long-term disease control using therapeutic immunomodulation is a long-standing concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic stem cell transplantation that continues to provide potentially curative treatment for otherwise challenging diagnoses, recent years have seen impressive progress in immunotherapies for leukemias and lymphomas with immune checkpoint blockade, bispecific monoclonal antibodies, and CAR T cell therapies. Despite their success, non-response, relapse, and immune toxicities remain frequent, thus prioritizing the elucidation of the underlying mechanisms and identifying predictive biomarkers. The increasing availability of single-cell genomic tools now provides a system's immunology view to resolve the molecular and cellular mechanisms of immunotherapies at unprecedented resolution. Here, we review recent studies that leverage these technological advancements for tracking immune responses, the emergence of immune resistance, and toxicities. As single-cell immune monitoring tools evolve and become more accessible, we expect their wide adoption for routine clinical applications to catalyze more precise therapeutic steering of personal immune responses.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11180218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0